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ABSTRACT
Despite current research towards applications of polymeric drug delivery systems (DDSs)
in biomedical research, significant limitations—specifically in synthetic accessibility, bio
compatibility, and principles of molecular self-assembly—have been discerned. To address
these drawbacks, we will investigate the synthesis and characterization of
heterobifunctional linear-dendritic block copolymers (LDBCs), which combine the
advantageous properties of both linear and dendritic blocks to afford nanomaterials with
superior mechanical properties. Our LDBC systems contain two differing functional
constituents, namely a hydrophilic polyamidoamine (PAMAM) dendron covalently linked
to a hydrophobic polyester (polylactic acid, or PLA), and can self-assemble to form
nanoparticles of various morphologies that serve as the vehicles for drug delivery. The
initial amine-terminated PAMAM is not ideal in biological systems due to a high positive
surface charge yielding concerns over cytotoxicity, so various functional groups were
incorporated at the hydrophilic block to not only investigate biocompatibility, but also to
discern interfacial surface behavior of these nanoparticles. These additional structural
modifications are important as they provide several biological advantages such as
resistance against plasma proteins and efficient cell penetrating ability. The synthesis of
well-defined PAMAM-polyester LDBCs was confirmed via spectroscopic and
chromatographic analysis. Microscopy and light scattering techniques afford evidence of
nanoparticle formation. The results of the study regarding terminal group alteration
demonstrated observable differences in parameters related to biocompatibility and confirm
that these materials are indeed applicable for targeted drug delivery.
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INTRODUCTION

Polymeric drug delivery systems (DDSs) hold considerable promise in both therapeutic
and diagnostic medical applications. DDSs act as integral transportation mechanisms to
ensure not only proper drug location is maintained on a tissue-specific level, but also
provide a consistent concentration of drug to those tissues through controlled degradation
or “time-release” capabilities. Being both therapeutic and diagnostic, these wide-ranging
“theranostic” properties1 are relevant to applications from cancer, where a lack of
specificity in harmful drugs is a major setback2, to ocular disease, in which consistent drug
concentration is a challenge.3 Other useful theranostic applications include medical
imaging dyes, which require a delivery method,4 and gene therapy, where cell perforation
is tantamount.5,10
Emerging in the literature are hybrid materials such as linear dendritic block
copolymers (LDBCs) which combine the advantageous properties of both linear and
dendritic macromolecules. Amphiphilic LDBCs are composed of segments of
fundamentally different molecular architecture and chemical property (i.e., hydrophilic and
hydrophobic). The immiscibility of hydrophilic and hydrophobic segments leads to
nanophase-segregation. Consequently, a unique property exhibited by these polymers is
the formation of various types of nanoparticles in water depending on the ratio between the
hydrophilic and hydrophobic construct. In contrast to traditional block copolymers and
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dendrimers, the nanostructures from LDBCs possess superior mechanical properties as
well as high degrees of molecular uniformity.
However, synthetic barriers, such as solubility, large-block sterics, and dendrimer
purity, as well as questions of biocompatibility and cytotoxicity, have limited the use of
certain polymeric DDSs. In addition, size and morphology play an important role in how
cells respond to and interact with these materials. The electrical potential, or surface
charge, greatly affects their biological interactions. This DDS surface charge affects not
only cellular uptake, but also whether a cell remains viable after contact, 7 as well as what
cellular uptake pathways8 and even cellular receptors9 a particle employs.
Herein, in defining a stable DDS that utilizes receptor-mediated endocytosis as an
uptake pathway, we will discuss the work to attain a target of relatively monodispersed
bilayer vesicles, via LDBC self-assembly, of around 60 nm in size with a slightly positive
zeta (ζ) potential, around 10-20 mV. This ζ potential is a measure of the electric potential
difference between a particle’s surface and the surrounding bulk liquid at their interface. It
is therefore akin to surface charge, though it is measured an ion layer farther away from
the particle’s surface at a region known as the electrical double layer, or “slipping plane,”
where ions, often both positive and negative, may be present and attracted to both the
particle itself as well as its surrounding ions.
The research focus herein aims to employ effective synthetic strategies to produce
various polymeric constructs within which the hydrophobic to hydrophilic ratio can be
altered alongside varying the end groups to obtain nanoparticles with biologically relevant
surfaces. With the aim of creating uniform bilayer vesicles, we explore reliable synthetic
pathways via the “dendrimer-first” approach, where the initial dendritic polymer acts as a
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macroinitiator for ring opening polymerization, to attain the precursor LDBCs. We also
study the effects of functionalization on these building blocks. In addition, alterations in
constituent ratios can alter the properties, especially morphology, size, and surface charge,
of the resulting delivery systems. Finally, we study the effects of these ratios on selfassembly in the size, shape, and charge of resulting nanoparticles.
The amphiphilic LDBCs explored here consist of a linear hydrophobic polymer,
PLA, and a dendritic hydrophilic polymer, PAMAM. The hyper-branched amine ends of
the initial whole-generation PAMAM dendrimer allow for useful conjugations. By altering
the surface chemistry through such conjugations, these particles are made tunable in their
surface charge and cellular interaction, thus increasing their biological effectiveness. The
biocompatible and biomimetic nature of PLA and PAMAM makes them ideal constituents
of a biologically innocuous LDBC, which serves as the molecular subunit for which the
larger nanoparticle DDS is based. The formation and basic architecture of such
nanoparticles is illustrated in Figure 1 below, with both hydrophilic constituents (red) and
hydrophobic constituents (blue) demarcated. This amphiphilic nature allows both
hydrophilic and hydrophobic drug encapsulation, making these systems especially
enticing.
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Figure 1. Basic assembly scheme of the DDS nanoparticles. The LDBCs are shown, at top
forming micelles, nanotubules, and bilayer vesicles, with red denoting the hydrophilic
PAMAM dendrimer portion, and blue denoting the linear hydrophobic polyester portion.
Upon the use of various precipitation techniques (to be explained more fully in the
Background section below), including normal nanoprecipitation (NNP), reverse
nanoprecipitation (RNP), and direct dissolution (DD), at varied polyester to dendrimer
ratios, self-assembly of multiple macromolecular morphologies was observed. These
morphologies include bilayer vesicles and worm-like micellar nanotubules. The
nanoparticle size was also shown to increase as the proportion of the hydrophobic polyester
portion increased. Alterations in the terminal groups of the hydrophilic PAMAM
constituent, between amine or carboxylate, effect the surface charge of the resulting
nanoparticles and prompt future research toward understanding biological interactions
through PAMAM functionalization. Such findings will further strengthen the already
enticing appeal of these amphiphilic heterobifunctional LDBCs as viable delivery systems
for clinical use.
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BACKGROUND

Since their inception by Fréchet et al. in 1992 with poly(ethylene oxide), or PEO, and
poly(benzyl ether), or PBE, compounds,11 amphiphilic LDBCs have been hailed as
revolutionary materials. Though initially viewed as useful abiotic phase-transfer reagents,
encapsulation compounds, and emulsifying agents, 12 LDBCs now offer considerable
promise as biomaterials. This was prompted by their discerned proclivity for microphase
separation, and their ability to self-assemble into varied morphologies, as first reported by
Meijer et al. in 199911 through polystyrene (PS) and carboxylic-acid-functionalized
poly(propylene imine), or PPI, LDBCs.13 The status of LDBCs is also due to its ability to
encapsulate a wide variety of materials, as well as the more recent utilization of
biocompatible substances in their structures, such as polyethylene glycol (PEG) and
diethylenetriamine,2 or PLA and PAMAM.14
In bringing together both the linear and dendritic constituents in the LDBC
molecule, three distinct synthetic routes may be taken: coupling, chain-first, or dendrimerfirst.11 The coupling route is the use of a reaction to bind the two already fully-synthesized
constituents, such as in the use of the Williamson reaction by Fréchet et al. 11 in the first
LDBC synthesis. Coupling is excellent when smaller, sterically-available molecules are
linked, but it is not ideal when considering bulkier, sterically-hindered constituents. The
chain-first route is the use of a fully-synthesized linear polymer chain as the base for
dendritic polymer growth, which was popularized by Meijer et al. via PS-PPI LDBCs in
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the 1990s.11 The chain-first method avoids concerns of sterics but may pose issues
regarding solubility and reaction conditions. The dendrimer-first route is the use of a fullysynthesized dendritic polymer as a base for the linear polymer growth. This route also
avoids steric concerns, is ideal for ring-opening polymerizations, and allows for minimal
solubility issues and side reactions due to the possibility of dendritic terminal-group
protection prior to polymerization.
Of the LDBC’s self-assembled supramolecular structures, micelles, nanotubules,
and vesicles have been reported, with vesicles holding the greatest promise. Polymeric
vesicles, being a low-energy conformation, have the advantage of mechanistic stability. 6
These vesicles also provide the advantage of tunability, for the physical, chemical, and
biological properties, including encapsulation retention, may be altered through variations
in properties, such as block length, structure, and extraneous molecular conjugation. 6
On account of tunability in amphiphilic block polymer systems, increasing the
hydrophobic to hydrophilic ratio (increasing the hydrophobic polyester weight) produces
an increase in both particle size and polydispersity index (PDI). 1 Similar to this trend, it is
reported that an increase in the hydrophobic portion when compared to the hydrophilic
portion of an LDBC alters the morphology of the polymeric aggregates, transitioning from
spherical micelles to both spherical and rod-shaped micelles, then finally to bilayer
vesicles, which is driven by the effects of surface tension minimization. 15
To date, LDBCs have been studied through a wide range applications, such as
electrochemistry and photoluminescence, crystallization and biomineralization processes,
and material encapsulation, carry, and release.11 Electrochemistry of this material class was
explored by Wang et al. through the synthesis, study, and comparison of two LDBCs
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containing a linear poly(ferrocenylsilane) (PFS) chain and either a generation 1 (G1) or G2
PBE dendrimer.11 Furthermore, regarding crystallization, Chen et al. in 2008 reported the
biomineralization of calcium carbonate using an LDBC comprised of a linear PEO chain
and a dendritic bis(hydroxymethyl) propionic acid polymer, finding that the larger dendron
had an insulating effect on the charge.11
LDBC nanoparticle encapsulation and controlled-release capacities primarily
involve biomedical enterprises. Among these are medical imaging and drug delivery,
especially regarding cancer.2 In 2013, Radosz et al. reported the increased circulation and
biodispersity of rod-shaped micelles consisting of linear-PEG-block and dendriticpolylysine-block LDBCs to encapsulate the hydrophobic anti-cancer drug camptothecin. 16
Furthermore, also in 2013, Gu et al. reported the successful encapsulation and prolonged
drug clearance of docetaxel, a known antitumor drug, within PAMAM-PDLA LDBC
micelles.14
LDBCs, especially of micellar morphologies, have yet to be utilized in commercial
medicine. This is in part due to the lesser mechanical stability in the micelle structure, 6 as
well as a limited encapsulation volume and limited chemical properties for encapsulated
materials (hydrophobic only). However, the chemical counterpart to vesicular LDBCs,
liposomes, are commercially available. Doxil®, an injectable, encapsulated form, via a
PEG-ylated liposome, of the well-known cancer drug doxorubicin, 17 has been approved in
the U.S. since 1995. Therefore, there is considerable possibility in vesicle-like LDBC
DDSs, such as those we are aiming at here.
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Scientific Approach
In designing our amphiphilic LDBCs, we chose PAMAM as the dendritic,
hydrophilic constituent. Since its initial synthesis by Tomalia et al. in 1985, PAMAM, with
its branched nature and highly controllable growth, has become incredibly popular, even
becoming the first commercially-available dendrimer.18 It is this controllable, systematic
synthesis which allows for low polydispersity and high structural control, as well as the
large number of functional surface sites relative to the total molecular volume, that made
this material an ideal choice in our DDSs. This branched structure and the resulting surfaceto-volume ratio also allows for greater encapsulation within polymeric “folds,” 5,20 and
makes this material ideal for drug uptake. Also, the interior amide bonds mimic biological
chemistry with their likeness to the polypeptide backbone structure of proteins. The
resulting properties, akin to those of globular proteins, allow the PAMAM to remain
biocompatible, making it useful for drug delivery. 19
At the structural level, PAMAM is a quadratically branched, amide-bond
containing polymer that is grown stepwise through alternating Michael additions and
amidations with two principal materials, MA and EDA, respectively. PAMAM was
initially synthesized to exhibit a “starburst” architecture, with a single trivalent amine core
branching into three separate dendrons. However, substitution of this initial PAMAM core
with a divalent amine, such as ethanolamine, allows for single-branch or individualdendron construction. Due to the step-wise quadratic growth of PAMAM, its generations
are denoted by most-terminal branching points, as seen in Figure 2 below, with one being
G1 (red), two being G2 (purple), four being G3 (blue), and so on. That means the number
of end groups is equal to double the number of branching points, as well as equal to 2 G,
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with G being the generation number. For example, standard PAMAM G3 has 4 branching
points at its farthest terminal end and 8 terminal amines.

Figure 2. PAMAM schematic illustrating the symmetric and geometrically sequential
nature of the dendrimer, as well as the generation naming system based on branching
points. One branching point, with two branches, is G1 (red), two points with four branches
is G2 (purple), and four points with four branches is G3 (blue), and so on.
Although PAMAM’s repeating amide groups allow for its biomimetic and thereby
biocompatible properties, the standard amine-terminated PAMAM dendrimer is known to
be cytotoxic. This is due to an excessive positive surface charge elicited by the terminal
amines, which remain protonated at biological pH.20 Alterations in PAMAM, such as the
acetylation of the terminal amines for oral drug delivery, have been reported with the hopes
of decreasing cytotoxicity.7 Exploration of more negative moieties, such as carboxylterminated dendrimers, has shown decreased toxicity, but lesser interaction with the
negatively charged cell surface.15 Therefore, a slightly positive ζ potential, of around +10
to 20 mV, is ideal for vesicular DDSs, and is a current area of study. Regardless, these
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alterations focus solely on purely dendritic DDSs and have not been directly correlated
with LDBC aggregate formations, which is an area we seek to expand upon.
Altering PAMAM terminal groups allows for greater functionalization with ligands
or other biomaterials,7 as depicted in Figure 3 below regarding the dendritic segment (red).
These terminal groups may be added to varying generation through many methods, such
as acylation, Michael addition, and amidation. The branched structure of PAMAM also
allows for greater hydrophilic drug uptake, which can occur in the pockets or folds of the
dendrimer.5

Figure 3. A chemical structure representing a single, fully-synthesized LDBC, PLAPAMAMG3-NH3+. The red section represents the hydrophilic dendritic PAMAM side,
while the blue represents the hydrophobic polyester PLA side.
The complete LDBC consists not only of this PAMAM constituent, but also the
linear, hydrophobic polymer constituent (shown as blue above in Figure 3). Polylactic
acid, or PLA, was chosen as it is well-studied and widely-used in medical applications. 19
This wide medical use, as well as the decision to include it our systems, is due to its
mechanical stability, biocompatibility, and biodegradability. Specifically, it can be
10

degraded via hydrolytic de-esertification to lactic acid,21 a common waste product of
metabolic fermentation as well as a key component in gluconeogenesis. Despite this
biodegradability, poly-L-lactic acid (PLLA), is more stable and crystalline than similar
polyesters, such as poly-DL-lactic acid (PDLLA), and so has a longer degradation time. 20
This increased degradation time makes PLLA especially useful for prolonged drug release.

Figure 4. Graphical representation of the drug-loading capabilities of amphiphilic bilayer
vesicles. In the presented systems, the hydrophilic portion, represented by red in the
images, is dendritic and is only shown represented as spherical (above left), though the true
shape is still dendritic. The hydrophobic polyester portion above is represented by the
linear blue segments.
As the hydrophobic moiety, PLA will be held internally within bilayer vesicles and
not affect the surface chemistry or surface charge of the nano-particle. However, as
illustrated in Figure 4 above, this internal architecture allows for not only covalent
functionalization of the polymeric end groups, but also the encapsulation of hydrophobic
drugs, which is unique to these amphiphilic LDBC vesicles.15 Solely dendritic DDSs, for
example, only encapsulate a single interactive class of molecules (usually hydrophilic), as
they do not consist of both hydrophobic and hydrophilic constituents. This heightened
11

hydrophobic capacity for encapsulation and conjugation, as well as PAMAM’s capacity
for conjugation with ligands and encapsulation of hydrophilic drugs, paired with the
biocompatible nature of these materials, makes this vesicular structure formed from PLAPAMAM LDBCs a particularly promising DDS.
Self-assembly of these LDBCs into these supramolecular morphologies can be
done through a variety of techniques. Precipitation techniques, such as NNP, RNP, and
DD, are those in which LDBC molecules are solvated by either water or an organic solvent
and are then added dropwise into a vortex or sonicating second solvent. This sonication
ensures that greater hydrophobic interactions occur among the polymer portion of the
LDBC molecules, which allows the LDBCs to assume the most energetically stable
confirmations via the exclusion of water by the hydrophobic moieties. NNP is performed
through solvating the LDBCs with an organic solvent, then adding the resulting solution to
sonicating water. Similarly, RNP is adding water to sonicating solvent with suspended
LDBCs. Both NNP and RNP end with removal of the organic solvent via air drying, while
DD is the addition of LDBCs to sonicating water free of any solvent. The resulting
nanoparticles may then be characterized and studied to ascertain their size, morphology,
and surface charge to determine which LDBC characteristics endow the most ideal DDS.
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RESULTS AND DISCUSSION

The PAMAM Dendron

Figure 5. An illustration of the hydrophilic block synthetic targets (left to right), amine
(NH3+) terminated, hydroxyl (OH) terminated, and carboxylate (CO2-) terminated G3
PAMAM.
The dendrimer-first approach, rather than the coupling or chain-first approaches, 11 is used
in this project for LDBC synthesis. This approach entails completely growing the initial
PAMAM dendrimer (one of the three examples shown in Figure 5 above) first, before the
polymerization that adds the linear portion is performed. This method eliminates concerns
regarding heating and other reaction conditions and minimizes steric issues through the use
of a ring-opening, or “living,” polymerization. This polymerization technique also affords
us synthetic control over the hydrophobic to hydrophilic polymer weight ratios.
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The initial growth of the dendron begins with the core, ethanol amine, and the halfgeneration reagents, MA and EDA. Through a Michael addition with MA, the half
generation (PAMAM G0.5) is synthesized, while an additional amidation with EDA
produces the even generation (PAMAM G1.0). Therefore, as depicted in the first few steps
of Figure 6, through six successive Michael additions and amidations, a generation three
PAMAM dendron is grown. Figure 6 goes on to show the complete protected, prepolymerization dendron, which will be addressed more fully later in this the “PAMAM
Terminal Functionalization” subsection.

Figure 6. The generalized PAMAM dendrimer synthesis scheme from initial core to final,
pre-polymerization product. The three arrows signify the alteration of Michael addition and
amidation steps up to PAMAM G3.0. After the final acylation step, Boc acts as a protecting
group for the amine-terminal during polymerization.
Due to the similarity in these alternating steps, nearly identical synthesis and
workup procedures can be used for successive generations of PAMAM. Such identical
procedures allow for the development of simple, repeatable, and highly effective methods
for high-efficacy generation growth. These steps and procedures are detailed in the
Synthesis Schemes section below.
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Due to the high reactivity of the divalent amines, the non-PAMAM reagent (MA or
EDA) in a growth reaction was routinely cooled to below 0°C via a salted ice bath, to
prevent excessive exothermic heat release. Though still done, this was not as necessary
during the Michael addition reactions that yield half-generations as it was during the
amidation reactions that yield whole-generations because MA is less reactive than EDA
and so the Michael addition produces less heat.
The workup, though uniformly applied to different generations, did change
throughout the course of PAMAM production as additional knowledge was gained.
Initially, a precipitation into either hexane or a 3:1 ether/hexane solution was performed
after each additive step to limit heat exposure to the PAMAM in evaporating EDA or MA.
However, there was a notable loss of product, with resulting yields of 70% for a product
that had continued to 100% reaction completion, as confirmed by 1H NMR. This was likely
due to inadequate settling of the precipitate before the next step occurred, as well as slight
product solubility in large solvent volumes. In an effort to increase yields, rotary
evaporation of both solvent and starting reagent was attempted at various temperatures with
differing amounts of higher-boiling-point (than MeOH) solvents, such as butanol and
reagent alcohol, to determine feasibility. This approach was successful. PAMAM is more
thermodynamically stable than initially expected, especially when heavily solvated. As a
result, the loss of product was greatly decreased from step to step.
However, precipitation still occurs during the workups for tert-butoxycarbonyl
(Boc) and tert-butyl ester (TBE) terminal PAMAMs, (both of which are illustrated in
Figure 7 below) due to the larger size and higher boiling point of their starting molecules,
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Boc anhydride and tert-butyl acrylate (TBA), respectively. At these steps there may be
lower yields, but the PAMAM synthesis process as a whole results in much less loss.
As detailed earlier, the temperature “cap” on this rotovap workup is variable but
decreases with time and concentration. The longer a PAMAM sample is under rotary
evaporation, especially with low to minimal solvent concentration (around 25 wt%) the
lower the temperature should be. A maximum temperature of 60°C can be used for short
periods of time with excess high-boiling solvents, such as BuOH, but to prevent crosslinking, a temperature of 50°C or below must be used for prolonged periods or with less
solvent present. To avoid this cross linking and degradation, denoted by a darkened color,
temperatures should remain below 50°C at these medium solvent concentrations, and
around 30°C when almost completely dry.
As likely inferred, this process of dendrimer growth is time-intensive. As a result,
similar studies have sought the use of commercially-available dendrimers, yet the decision
to synthesize this material in-lab is multi-faceted. First, the use of self-made material yields
greater synthetic control over the process and results in a product with minimal extraneous
aggregates. Second, despite the time-saving aspect, additional purification steps are
required before the use of commercially-available dendrons occurs. Purification takes time
in itself and, paired with the high cost of these commercial materials, makes their use
unjustifiable. Finally, in synthesizing these materials, we maintain control over varied
cores and terminal groups which may not be commercially available.
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PAMAM Terminal Functionalization
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Figure 7. Functionalized hydrophilic targets, Boc protected (left) and TBE protected
(right) G3 PAMAM, which act as the precursors to the deprotected NH3+ and CO2terminated PAMAM targets, respectively.
The goal of altering PAMAM end groups was to not only allow for varied terminals
from which additional prodrugs or ligands can be bound, but also to decrease the surface
charge and cytotoxicity of the PAMAM constituent, as well as to protect the PAMAM
terminal groups while polymerization is occurring. This functionalization of the PAMAM
dendrimers occurred at several generations and under varied conditions, depending on the
terminal group and addition method in question.
As PAMAM is tasked as the hydrophilic LDBC constituent, the added groups all
share that attribute. The three terminal groups of focus, as seen in Figure 5 above, are
NH3+, which uses Boc to act as a protecting group for the terminal amine, CO 2-, which uses
TBE as a protecting group for the carboxylic acid or carboxylate group, and OH, which
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currently does not take advantage of a protective group, though this is currently an ongoing
area of research. It will be briefly addressed later in the “Functionalized Size and Surface
Charge Studies” subsection (see Figure 20 below). However, the Boc and TBE protecting
groups of PAMAM G3.0 dendrimers can be seen in Figure 7 above.
Boc addition, performed via an acylation with Boc anhydride, was performed using
the terminal amines of whole generation PAMAM (G3.0 for example) as a substrate. TBA,
however, was added via a Michael addition, similar to how MA was added in producing a
half-generation PAMAM. The resulting geometric branching from the terminal amines
mean that a whole-generation PAMAM at one generation level below the intended
generation was used (G2.0 as a substrate for G3.0-TBE) to form TBE terminated PAMAM.

LDBC Formation via Polymerization

Figure 8. Full LDBC synthetic scheme, from initial PAMAM starting materials, through
generation growth, functionalization, polymerization, and deprotection. The two colored
structures represent our already synthesized NH3+ and CO2- terminated LDBC targets.
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A full synthetic scheme is depicted in Figure 8. As previously discussed, PAMAM
acts as a macroinitiator for ring opening polymerization (Fig. 9). This step was undertaken
with the aid of a senior labmate and graduate student, Indika Chandrasiri. This
polymerization uses the hydroxyl core of PAMAM as the macro-initiator and was
performed using cyclic lactide as the monomer for polymerization. To determine the
maintained reactiveness of the free, initiated PAMAM hydroxyl group for polymerization,
an overnight, unheated test reaction using acetic anhydride was performed. 1HNMR was
used to determine reaction completion through the shift of the methyl group on acetic
anhydride from 1.14 ppm to 2.05 ppm. When this shift is seen, acetic anhydride binding
has occurred, which supports the availability of the PAMAM core hydroxyl for separate
polymerization reactions with unreacted PAMAM material. Due to the possibility of
forming hydrophobic polyester aggregates with extraneous hydroxyl groups, even those
present in water, during polymerization, intense purification and reaction under dry
conditions was performed. Three recrystallizations via toluene at 120°C, followed by 3-5
days of vacuum-drying, ensured no water was present. As a precaution, extra-dry
compressed nitrogen was used in these polymerization reactions.
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Figure 9. Ring opening scheme and polymerization mechanism of PLA with the PAMAM
hydroxyl group acting as the micro-initiator to form the final PLA-PAMAM LDBC.
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The weight percentage of polyester to dendrimer used in the reaction to form the
LDBCs was varied, somewhat arbitrarily, by factors of twenty in order to investigate how
variances in weight ratios affected nano-particle morphology post self-assembly. The first
number in the following descriptions denotes the PLA percentage, while the second
denotes the PAMAM percentage. A polyester ratio of 30 wt% PLA to 70 wt% PAMAM
(30/70) was the lowest chosen; any lower and there would likely be insufficient
hydrophobic volume to engender vesicular or morphological self-assembly. Next, ratios of
50/50, 70/30, and 90/10 were used.
Initially, chloroform was used as the reaction solvent, for the two central reagents,
PAMAM and PLA, are soluble in it, while addition of the 1,8-Diazabicyclo(5.4.0)undec7-ene (DBU) was completed via chlorobenzene. Later solubility tests of DBU proved
chloroform to be an adequate solvent, and its lone use simplified the procedure.
After the polymerization is performed, the protected PAMAM terminal groups are
deprotected, as depicted in the latter parts of “STEP 3” in Figure 8 above. The removal of
the protected groups, such as Boc or TBE, results in the final NH3+ or CO2- terminated
PAMAM, respectively, and is done via acidification with trifluoracetic acid (TFA) or HCl,
respectively. This is done to restore the amphiphilic properties to the LDBC, making them
capable of self-assembling into nanoparticles via the three precipitation methods, NNP,
RNP, and DD, outlined below.
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Nanoparticle Assembly and Morphology Results
The primary assembly method used to form the intended vesicular systems in this
study is that of NNP, which is outlined in Figure 10 below. Again, NNP is performed
through solvating the LDBCs with an organic solvent, then adding the resulting solution to
sonicating water. However, the use of solvents at all in self-assembly, such as through the
NNP and RNP techniques, is not ideal, for the final goal in these particles is biological
application and many organic solvents are recognized as hazardous to cellular life.
Therefore, another precipitation method, DD, has been explored and is currently the most
promising future method. Again, DD is the addition of LDBCs to sonicating water free of
organic solvent, which decreases possible complications with future biological systems.

Figure 10. Graphical representation of NNP scheme as used for the vesicular formation of
LDBCs.
In order to study the effects of hydrophobic to hydrophilic ratios on the selfassembled nanoparticle morphology, four different LDBC treatments were synthesized at
varied concentrations of hydrophobic PLA, specifically PLLA, to hydrophilic PAMAM.
The goal here is to observe different morphologies and identify which concentrations were
most useful for drug delivery applications. These four treatments, as stated above, were as
follows: 30 wt% PLLA to 70 wt% PAMAM (30/70), 50 wt% PLLA to 50 wt% PAMAM
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(50/50), 70 wt% PLLA to 30 wt% PAMAM (70/30), and 90 wt% PLLA to 10 wt%
PAMAM (90/10). These treatments were assembled using NNP and were visualized using
uranyl formate contrasting agents for transmission electron microscopy (TEM), as well as
dynamic light scattering (DLS).
In interpreting the data, distinctions must be made between the different size
measurement techniques and values used. DLS provides size information in multiple
forms. One is hydrodynamic diameter, which is represented by the peak apex in the DLS
spectra below and is the measured diameter of an aggregate, along with the thin ion and
solvent layer that adheres to its surface, as it undergoes Brownian motion in solution.
Another, the Z-Avg, also known as the intensity-weighted harmonic mean, is a calculated
measure akin to the particle’s core size (free of associated ions and solvent) and is therefore
closer to the reported TEM value than the hydrodynamic diameter. The y-axes of the
following DLS spectra are measured via intensity percentage, which is a relatively arbitrary
measurement related to the scattering intensity of each particle in the sample.

30/70 PLLA – PAMAMG3.0-NH3+
This treatment examined the smallest weight percentage of PLA used. Due to this
small amount of polyester, the expectation was that a small micelle would be formed under
NNP methods. However, what appeared to be a 20 to 25 nm in diameter bilayer vesicle
was instead formed and is visualized below in Figure 11 via TEM. The thick dark ring
surrounding a light interior, indicating two layers, is strong evidence that a bilayer vesicle
was indeed formed. Therefore, it would appear that, at least in this instance, the
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encapsulated internal volume of the particle had a greater bearing on the resulting
morphology than the hydrophobic to hydrophilic weight ratio.

Figure 11. TEM image of 30/70 PLLA – PAMAM G3.0-NH3+ sample exhibiting a bilayer
vesicle morphology with a diameter ranging from 20 nm to 25 nm. Visualized occurred
under a uranyl formate contrasting agents.
This 20 to 25 nm diameter size is corroborated by the following DLS data in Figure
12 depicting a 30 nm particle via the leftmost peak. Aggregates (not visualized in the TEM)
also appeared in the DLS spectra at a larger diameter as seen in the DLS via the rightmost
peak. This additional aggregate is not ideal for our systems, as a low poly-dispersity is ideal
for maintaining property control.
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Figure 12. DLS spectra of 30/70 PLLA – PAMAM G3.0-NH3+ sample bilayer vesicles.
Average hydrodynamic diameter for resulting vesicular morphologies is 30 nm.
Aggregates were also seen.
Furthermore, this size is not ideal for the intended DDS application. A bilayer
vesicle at this 30 nm size, in theory, lacks the internal capacity, as well as the hydrophobic
inter-layer space, to act as a worthwhile theranostic drug carrier.

50/50 PLLA – PAMAMG3.0-NH3+
At 50 wt% PLLA to PAMAM, a mixture of micelles and vesicles was expected.
This treatment, however, showed even more varied morphologies. The TEM data, seen in
Figure 13 below, showed both vesicles and “worms,” or non-uniform globular
microtubules, with diameters ranging from 30 to 40 nm in size. These varied morphologies
occur because there are an array of energetically favorable arrangements for the LDBC
molecules to assume at this weight percentage, and, though not explicitly visualized, there
is a high likelihood that micelles may also be produced in similar treatments.
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Figure 13. TEM image of 50/50 PLLA-PAMAM G3.0-NH3+ sample vesicles and worms.
Morphology diameter of vesicles range from 30 nm to 40 nm while the worm diameter is
about 25 nm; both were visualized under a uranyl formate contrasting agents.
The 30 to 40 nm diameter size of the worms and vesicles determined by the TEM
is not explicitly corroborated by the DLS spectra in Figure 14. Due to the broad array of
morphologies seen at their varied positions, which can be interpreted by the fixed-angled
DLS as vastly different sizes, the diameter size is inconclusive. Nevertheless, two peaks, a
“dominant peak” and a “phantom peak,” are seen which supports that these two
morphologies likely appeared and are relatively close in size.
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Figure 14. DLS spectra of 50/50 PLLA – PAMAM G3.0-NH3+ sample vesicles and
worms. Average hydrodynamic diameter for resulting vesicular morphologies is near that
of the TEM image, illustrating two overlapping distributions, though the diameter value is
not completely determinable due to the width of the spectra.
Having multiple morphologies occur in a single treatment is not ideal, for not only
does it produce a higher PDI, but little reliability regarding particle properties is
guaranteed. The intended uniform particle distribution aims to produce nearly identical
DDSs whose properties remain reliably similar; the 50% polyester treatment falls short in
this regard.

70/30 PLLA – PAMAM G3.0-NH3+
This third treatment at 70 wt% polyester yielded TEM confirmation of relatively
monodispersed bilayer vesicles, especially when compared to the 50% polyester treatment,
of 50 to 65 nm. This bilayer vesicle is not only the target morphology and size, but is also
the only morphology present, making it more ideal from a dispersity standpoint as well.
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Figure 15. TEM image of 70/30 PLLA – PAMAM G3.0-NH3+ sample bilayer vesicles.
Morphology diameter ranges from 50 nm to 65 nm and were visualized under a uranyl
formate contrasting agents.
The TEM data is corroborated by the following Figure 16 DLS data, which shows
a diameter of 68 nm for the 70% polyester treatment vesicles. This is as intended and
follows the prevailing trend of DLS readings being slightly higher than those of TEM,
which is a result of the hydrodynamic diameter reported via DLS defining additional
solvated molecules beyond the smaller core size reported by the TEM.

27

Figure 16. DLS spectra of 70/30 PLLA – PAMAM G3.0-NH3+ sample bilayer vesicles.
Average hydrodynamic diameter for resulting vesicular morphologies is 68 nm.
Having this single bilayer vesicle morphology at 50 to 65 nm in diameter is ideal
not only for the dispersity and reliability of the DDSs in their properties, but also for the
intended uptake mechanism – receptor mediated endocytosis. 22 This treatment, 70%
polyester, will therefore remain the focus of future studies for forming these useful drug
delivery particles. However, that does not preclude the study of other treatments, for
morphologies and properties vary through alterations in terminal group functionalizations.

90/10 PLLA – PAMAM G3.0-NH3+
The increase in weight percentage of the polyester portion of the LDBC to 90%
showed dramatic alterations in the size of the material, though not in the morphology.
Bilayer vesicles were still reported, though the size ranged from 190 nm to 200 nm in
diameter via TEM (Fig. 17).
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Figure 17. TEM image of 90/10 PLLA – PAMAM G3.0-NH3+ sample bilayer vesicles.
Morphology diameter ranges from 190 nm to 200 nm and were visualized under a uranyl
formate contrasting agents.
DLS data supports this 190 nm to 200 nm size, with a diameter of around 204 nm.
This size increase and relationship is as expected, and no complicating peaks denote
additional morphologies. The Figure 18 peak does appear a bit wider, which can be
explained due to the increase in hydrophobic material producing more varied polyester
chain lengths that then result in a greater variance of vesicle size.
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Figure 18. DLS spectra of 90/10 PLLA – PAMAM G3.0-NH3+ sample bilayer vesicles.
Average hydrodynamic diameter for resulting vesicular morphologies is 68 nm.
This increase in size, though expected, is not ideal for our DDSs, for it overshoots
our target diameter of around 60 nm. The main pathway of uptake for these larger vesicles
would therefore likely be standard phagocytosis,22 rather than the intended receptormediated endocytosis. That is not to say they are not useful in applications of drug delivery,
but they are not preferred for our intended applications.

Functionalized Size and Surface Charge Studies
For the following size and surface charge studies, two different PAMAM end
groups were focused on – NH3+ and CO2-. The particles were formed via RNP and were
measured using DLS. The varied sizes shown in Figure 19 and Table 1 below, with the
CO2- terminal particles being larger than the NH3+ terminal particles by 170 nm, are
expected. With both LDBC samples using 90% polyester, this difference in size is likely
due to the different properties and sizes of the end groups. The internal PAMAM structure,
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being electron rich, more readily associates with the positively charged terminal amines
than the negatively-charged terminal carboxylates. This means the amine-terminated
nanoparticles would be more densely packed than the carboxylate-terminated
nanoparticles, resulting in their observed lower diameter.

Figure 19. DLS spectra constructed from two separate sample aggregates, 90/10 PLLAPAMAM G3-CO2- (green) and 90/10 PLLA-PAMAM G3-NH3+ (red) vesicles. Average
hydrodynamic diameter size was 223.1 nm and 53.04 nm in diameter, respectively.
Furthermore, the terminal-amine-containing vesicle was expected to have a positive
ζ potential, at around +64.8 ± 1.2 mV as reported in starburst PAMAM G7-NH 3+
dendrimers,10 while the terminal-carboxylate-containing vesicle was expected to have a
negative ζ potential, at around -42.0 ± 3.2 mV as reported in similar starburst PAMAM
G7-CO2- dendrimers.10 As seen in Table 1 below, these expectations were nearly realized
for both of the LDBCs, with the terminal amine displaying a ζ potential of +68.4 ± 0.839
mV, and the terminal carboxylate displaying a ζ potential of -38.4 ± 0.839 mV.
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Table 1. Particle size and surface charge data of 90/10 PLLA-PAMAM G3-CO2- (CO2-)
and 90/10 PDLLA-PAMAM G3-NH3+ (NH3+) vesicles is shown below. The zeta potentials
were negative, as expected, for the carboxylate and positive, as expected, for the amine.

Sample ID

NH3+

CO2-

Hydrodynamic Diameter (nm)

53.04

223.1

Z-Avg (d.nm)

45.83

178.9

PDI

0.128

0.278

ζ Potential (mV)

+68.4 ± 0.839

-38.4 ± 0.839

A positive ζ potential of less than +20 mV is ideal, as it is positive enough to be
attracted to the cell and undergo receptor-mediated endocytosis, but not so positive as to
initiate cell-death or perforate the cell wall. The resulting amine-terminated particles had a
positive ζ potential of around +68.4 mV, which would likely have cytotoxic effects on
biological systems. This is far from the intended application, so ways to lower the ζ
potential while still maintaining a slightly positive surface charge, such as interspersing
various terminal groups like negatively charged carboxylates or less positively charged
hydroxyls, which have a reported ζ potential of +27.7 ± 1.1 mV in G7 starbursts, 10 in the
same PAMAM molecule.
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Figure 20. Proposed synthesis scheme of the hydroxyl-terminated LDBC PLA-PAMAM
G3.0-OH starting from PAMAM G2.5
Simple hydroxyl group addition to PAMAM, forming a PAMAM-OH product as
seen in Figure 5 above, has been performed via ethanolamine through an amidation akin
to the use of EDA in the formation of a whole generation. Therefore, a half generation of
PAMAM serves as a reagent to form the intended hydroxyl-terminated whole generation,
such as G2.5 forming G3.0-OH as seen in Figure 20 above. This proposed synthesis
scheme uses a THP-protected ethanolamine as a monomer, which may be deprotected postpolymerization via acidification to yield the hydroxyl terminated LDBC target. Preliminary
studies have indicated this as a promising route, but such research is yet to be complete.
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CONCLUSION

Historically, viable drug delivery systems have struggled with poor or unstable drug
loading, limited chemical conjugation, and toxicity. Furthermore, barriers to PAMAM use
in these DDSs have included synthetic accessibility. We have proposed viable synthetic
routes to synthesize both PAMAM and the resulting LDBC DDSs as well as shown the
biocompatibility of these molecules through the alteration of substituent terminal groups
on the hydrophilic PAMAM dendrimers. The viability of these PAMAM-polyester LDBCs
as vesicular drug delivery systems has been demonstrated through 1HNMR, TEM, DLS,
and surface charge studies.
Now that viability has been ascertained, the focus must shift to fine-tuning
secondary properties, such as surface charge, encapsulation, and degradation, as well as
cellular adhesion and cytotoxicity via specific cellular assays. The surface charge in
particular is in the process of being curbed by graduate students through producing
PAMAM with alternating terminal groups to decrease the ζ potential of the cytotoxically
positive amine groups.
Furthermore, additional research on ligand or prodrug addition to ensure specificity
of the DDS to the intended delivery site will increase the usefulness of these particles. This
research is currently being undergone by graduate students in our lab and will provide
added data to support the efficacy of these mechanically self-assembled, vesicular LDBC
systems.
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SYNTHESIS SCHEMES

PAMAM Synthesis
Synthesis of PAMAM G0.5

Procedure:
An ethanol amine and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring MA and methanol solution (10 molar eq.; 20 wt%)
under salted ice. After complete addition of MA, the reaction was allowed to warm to room
temperature and a hot oil bath, held at 35°C was added. The reaction continued overnight.
Upon HNMR confirmation of completion, three rotovaps with BuOH, three with reagent
alcohol, and three with MeOH ensued until complete removal of MA was again confirmed
by HNMR in CDCl3.
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NMR:

Figure 21. 1H NMR of PAMAM G0.5 (300 MHz, CDCl3) δ 2.46- 2.51(2H, t), 2.59-2.63
(2H, t), 2.79-2.84 (4H, t), 3.56 – 3.60 (2H, t), 3.68(6H, s); Solvent impurity: MeOH δ 3.39
(3H, s)

Synthesis of PAMAM G1.0
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Procedure:
A PAMAM G0.5 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring EDA and methanol solution (20 molar eq.; 20 wt%)
under salted ice. After complete addition of EDA, the reaction was allowed to warm room
temperature and a hot oil bath, held at 35°C was added. The reaction continued overnight.
Upon HNMR confirmation of completion, three rotovaps with BuOH, three with reagent
alcohol, and three with MeOH ensued until complete removal of MA was again confirmed
by HNMR.
NMR:

Figure 22. 1H NMR of PAMAM G1.0 (300 MHz, MeOD) δ 2.34-2.38 (4H, t), 2.63 (2H,
t), 2.68-2.72 (4H, t), 2.78-2.83(4H, t), 3.21-3.25 (4H, t), 3.45 (2H, s), 4.87. Solvent
Impurities: n-BuOH δ 0.90-0.95(3H, t), 1.31-1.40 (2H, m), 1.43-1.54 (2H, m).
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Synthesis of PAMAM G1.5

Procedure:
A PAMAM G1.0 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring MA and methanol solution (30 molar eq.; 20 wt%)
under salted ice. After complete addition of MA, the reaction was allowed to warm to room
temperature and a hot oil bath, held at 35°C was added. The reaction continued for two
days. Upon HNMR confirmation of completion, three rotovaps with BuOH, three with
reagent alcohol, and three with MeOH ensued until complete removal of MA was again
confirmed by HNMR in CDCl3.
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NMR:

Figure 23. 1H NMR of PAMAM G1.5 (300 MHz, CDCl3) δ 2.38-2.40 (4H, t), 2.42-2.46
(8H, t), 2.53-2.57 (4H, t), 2.64-2.65 (2H, t), 2.73- 2.78 (8H, t), 2.81- 2.85 (4H, t), 3.27-3.29
(4H, t), 3.61, 3.63 (2H, t), 3.67 (12H, s); Solvent Impurities: CDCl 3 δ 3.42 (1H, s)
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Synthesis of PAMAM G2.0

Procedure:
A PAMAM G1.5 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring EDA and methanol solution (40 molar eq.; 20 wt%)
under salted ice. After complete addition of EDA, the reaction was allowed to warm to
room temperature and a hot oil bath, held at 35°C was added. The reaction continued for
three days. Upon HNMR confirmation of completion, three rotovaps with BuOH, three
with reagent alcohol, and three with MeOH ensued until complete removal of MA was
again confirmed by HNMR.
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NMR:

Figure 24. 1H NMR of PAMAM G2.0 (300 MHz, MeOD) δ 2.39-2.44 (12H, t), 2.60-2.65
(4H, t), 2.67-2.69 (2H, t), 2.75- 2.79 (8H, t), 2.81-2.85 (12H, t), 3.28-3.32 (12H, t), 3.353.36 (2H, t), 3.65-3.69 (2H, t); Solvent Impurities: MeOH δ 3.40 (s), BuOH δ 4.93 (s)
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Synthesis of PAMAM G2.5

Procedure:
A PAMAM G2.0 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring methyl MA and methanol solution (50 molar eq.;
20 wt%) under salted ice. After complete addition of MA, the reaction was allowed to
warm to room temperature and a hot oil bath, held at 35°C was added. The reaction
continued for four days. Upon HNMR confirmation of completion, three rotovaps with
BuOH, three with reagent alcohol, and three with MeOH ensued until complete removal
of MA was again confirmed by HNMR.
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NMR:

Figure 25. 1H NMR of PAMAM G2.5 (500 MHz, CDCl 3) δ 2.35-2.38 (12H, t), 2.42-2.45
(16H, t), 2.53-2.56 (8H, t), 2.57-2.59 (4H, t), 2.60 (2H, t), 2.74-2.81 (28H, m), 3.26-3.29
(12H, t), 3.62-3.62 (2H, t), 3.67 (24H, s). Solvent Impurities: δ IPA 2.49 (s); MeOH δ 3.44
(s).
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Synthesis of PAMAM G3.0

Procedure:
A PAMAM G2.5 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring EDA and methanol solution (60 molar eq.; 20 wt%)
under salted ice. After complete addition of EDA, the reaction was allowed to warm to
room temperature and a hot oil bath, held at 35°C was added. The reaction continued for
four days. Upon HNMR confirmation of completion, three rotovaps with BuOH, three with
reagent alcohol, and three with MeOH ensued until complete removal of MA was again
confirmed by HNMR.
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NMR:

Figure 26. 1H NMR (300 MHz, MeOD) δ 2.38-2.42 (28H, t), 2.59-2.61 (12H, t), 2.73-2.77
(16H, t), 2.81-2.84 (28H, t), 3.26-3.30 (28H, t), 3.64-3.67 (2H, t). Solvent Imputities: nBuOH δ 0.94-0.99 (t), 1.35-1.47 (m), 1.50-1.59 (m) 4.92 (s); MeOH δ 3.38 (s); t-BuOH
δ3.34 (s), 3.56-3.60 (t).
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Terminal Functionalization of PAMAM
Synthesis of PAMAM G3.0-BOC

Procedure:
A Boc Anhydride and methanol solution (80 molar eq.; 20 wt%) was added dropwise at 12 drops a second via separatory funnel to a stirring PAMAM G3.0 and methanol mixture
(50 wt%) and under salted ice. After complete addition of EDA, the reaction was allowed
to warm to room temperature. The reaction continued at room temperature for two days.
Upon HNMR confirmation of completion, a single rotovap ensued. The PAMAM product
was dissolved into x mL of DCM which was followed by a precipitation via separatory
funnel into 5x mL of stirring, pure hexane. After settling, the hexane layer was decanted,
and the remaining product was air-dried. This precipitation, decanting, and air-drying
process was repeated twice more. A final HNMR ensured the removal of Boc Anhydride.
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NMR:

Figure 27. 1H NMR of PAMAM G3.0-BOC (300 MHz, CDCl 3) δ 1.44 (72H, s), 2.37 (28H,
t), 2.55 (14H, t), 2.75 (28H, t), 3.26 (28H, t), 3.34 (20H, t), 3.64 (2H, t); Solvent Impurities:
DCM δ 5.32 (s); Chloroform δ 7.28 (s).
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Synthesis of PAMAM G3.0-TBE

Procedure:
A PAMAM G2.0 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring TBA and methanol solution (50 molar eq.; 20 wt%)
under salted ice. After complete addition of TBA, the reaction was allowed to warm to
room temperature and a hot oil bath, held at 35°C was added. The reaction continued for
four days. Upon HNMR confirmation of completion, three rotovaps with BuOH, three with
reagent alcohol, and three with MeOH ensued until complete removal of TBA was
confirmed by HNMR.

48

NMR:

Figure 28. 1H NMR of PAMAMG3.0-TBE (500 MHz, CDCl 3) δ 1.46 (72H, s), 2.36-2.38
(24H, t), 2.41 (4H, t), 2.56 (8H, t), 2.61 (4H, t), 2.74-2.77 (16H, t), 2.83 (12H, t), 3.30-3.31
(12H, t), 3.65 (2H, t); Solvent Impurities: MeOD 3.50 (s)
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Synthesis of PAMAM G3.0-OH

Procedure:
A PAMAM G2.5 and methanol mixture (50 wt%) was added dropwise at 1-2 drops a
second via separatory funnel to stirring ethanol amine and methanol solution (60 molar eq.;
20 wt%) under salted ice. After complete addition of EDA, the reaction was allowed to
warm to room temperature and a hot oil bath, held at 35°C was added. The reaction
continued for four days. Upon HNMR confirmation of completion, three rotovaps with
BuOH, three with reagent alcohol, and three with MeOH ensued until complete removal
of ethanol amine was confirmed by H1NMR.
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NMR:

Figure 29. 1H NMR of PAMAM G3.0-OH (500 MHz, MeOD) δ 2.39-2.41 (28H, t), 2.602.62 (12H, t), 2.68-2.84 (28H, t), 3.30 (12H, t), 3.33-3.35 (18H, t), 3.50 (2H, t), 3.62-3.65
(16H, t); Solvent Impurities: MeOH 3.37 (s), DCM 4.87 (s).
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LDBCs Synthesis via Polymerization
Synthesis of PLLA-PAMAM G3.0-NH3+

Procedure: Identical among PLA treatments, save reagent ratios
In a glove box, freeze-dried PAMAM G3.0-BOC and re-crystallized, dried lactide (X wt%
to PAMAM) were both weighed into a dry 2-neck round-bottomed flask (RBF) with side
valve, while DBU (2.5 eq. to PAMAM) was weighed into a separate 1-neck RBF. Septums
were then added to the RBFs before they were removed from the glove box. Each was then
solvated with CHCl3 and was stirred for 30 min. Then, the DBU RBF contents were added
to the main reaction flask containing PAMAM. The reaction was allowed to stir overnight
at 130°C. After the flask cooled, benzoic acid (2 eq. to DBU) was added to quench the
reaction under N2 and was stirred for an additional hour. To deprotect the Boc terminal
groups, the dried product was added to a clean, dry RBF with TFA and DCM, and was
stirred for 4 hours under N2.
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NMR:30 wt% PLLA

Figure 30. 1H NMR of 30/70 PLLA-PAMAM G3.0-BOC (400 MHz, CDCl 3) δ 1.44 (72H,
s), 1.57-1.60 (12H, t), 2.37 (28H, t), 2.55 (14H, t), 2.74 (28H, t), 3.26 (28H, t), 3.34 (20H,
t), 3.54 (2H, t), 5.17-5.23 (4H, m); Solvent Impurities: Chloroform δ 7.28 (s).
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NMR:50 wt% PLLA

Figure 31. 1H NMR of 50/50 PLLA-PAMAM G3.0-BOC (400 MHz, CDCl 3) δ 1.44 (72H,
s), 1.56-1.60 (53H, t), 2.35-2.38 (28H, t), 2.54-2.55 (14H, t), 2.73-2.75 (28H, t), 3.24-3.27
(28H, t), 3.32-3.35 (20H, t), 3.52-3.54 (2H, t), 5.16-5.23 (17H, m); Solvent Impurities:
Chloroform δ 7.28 (s).
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NMR:70 wt% PLLA

Figure 32. 1H NMR of 70/30 PLLA-PAMAM G3.0-BOC ( (400 MHz, CDCl 3) δ 1.44
(72H, s), 1.56-1.61 (207H, t), 2.36-2.39 (28H, t), 2.55-2.56 (14H, t), 2.75-2.76 (28H, t),
3.25-3.27 (28H, t), 3.33-3.35 (20H, t), 3.51-3.53 (2H, t), 5.17-5.23 (69H, m); Solvent
Impurities: Chloroform δ 7.28 (s).
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NMR:90 wt% PLLA

Figure 33. 1H NMR of 90/10 PLLA-PAMAM G3.0-BOC (400 MHz, CDCl 3) δ 1.44 (72H,
s), 1.56-1.61 (938H, t), 2.41 (28H, t), 2.59 (14H, t), 2.78-2.80 (28H, t), 3.25-3.27 (28H, t),
3.34 (20H, t), 3.51-3.52 (2H, t), 5.17-5.27 (309H, m); Solvent Impurities: Chloroform δ
7.28 (s).

56

LIST OF REFERENCES

1.

Makino, A., Hara, E., Hara, I., Ozeki, E., & Kimura, S. (2014). Size control of core-

shell-type polymeric micelle with a nanometer precision. Langmuir: The ACS Journal of
Surfaces and Colloids. 30(2), 669.
2.

Dai, X., Fan, W., Wang, Y., Huang, L., Jiang, Y., Shi, L., . . . Tan, C. (2016).

Combined delivery of let-7b MicroRNA and paclitaxel via biodegradable nanoassemblies
for the treatment of KRAS mutant cancer. Molecular Pharmaceutics. 13(2), 520.
3.

Vandamme, F., L., Brobeck, (2005). Poly(amidoamine) dendrimers as ophthalmic

vehicles for ocular delivery of pilocarpine nitrate and tropicamide. Journal of Controlled
Release. (102)1, 23-38. https://doi.org/10.1016/j.jconrel.2004.09.015.
4.

Pramod, P. S., Takamura, K., Chaphekar, S., Balasubramanian, N., & Jayakannan,

M. (2012). Dextran vesicular carriers for dual encapsulation of hydrophilic and
hydrophobic molecules and delivery into cells. Biomacromolecules. 13(11), 3627.
5.

Kesharwani1, P., Banerjee, S., Gupta, U., Amin, M., Padhye, S., Sarkar, F., and

Iyer, A. (2015). PAMAM dendrimers as promising nanocarriers for RNAi therapeutics.
Materials Today. 18(10), 565-572.
6.

Tian, L., Nguyen, P., & Hammond, P. T. (2006). Vesicular self-assembly of comb-

dendritic block copolymers. Chemical Communications (Cambridge, England). (33), 34893491. 10.1039/B608363C

57

7.

Kolhatkar, R. B., Kitchens, K. M., Swaan, P. W., & Ghandehari, H. (2007). Surface

acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while
maintaining membrane permeability. Bioconjugate Chemistry. 18(6), 2054-2060.
10.1021/bc0603889
8.

Harush-Frenkel, O., Rozentur, E., Benita, S., & Altschuler, Y. (2008). Surface

charge of nanoparticles determines their endocytic and transcytotic pathway in polarized
MDCK cells. Biomacromolecules. 9(2), 435-443. 10.1021/bm700535p
9.

Fleischer, C. C., & Payne, C. K. (2012). Nanoparticle surface charge mediates the

cellular receptors used by protein-nanoparticle complexes. Journal of Physical Chemistry
B. 116(30), 8901-8907. 10.1021/jp304630q
10.

Greish, K., Thiagarajan, G., Herd, H., Price, R., Bauer, H., Hubbard, D., . . .

Ghandehari, H. (2012). Size and surface charge significantly influence the toxicity of silica
and

dendritic

nanoparticles.

Nanotoxicology.

6(7),

713-723.

10.3109/17435390.2011.604442
11.
art

Wurm, F., & Frey, H. (2011). Linear–dendritic block copolymers: The state of the
and

exciting

perspectives.

Progress

in

Polymer

Science.

36(1),

1-52.

10.1016/j.progpolymsci.2010.07.009
12.

Gitsov, I., Wooley, K. L., & Fréchet, J. M. J. (1992). Novel polyether copolymers

consisting of linear and dendritic blocks. Angewandte Chemie (International Edition in
English). 31(9), 1200-1202. 10.1002/anie.199212001
13.

Fan, X., Zhao, Y., Xu, W., & Li, L. (2016). Linear-dendritic block copolymer for

drug and gene delivery. Materials Science & Engineering: C, Materials for Biological
Applications. 62, 943. 10.1016/j.msec.2016.01.044

58

14.

Qiao, H., Li, J., Wang, Y., Ping, Q., Wang, G., & Gu, X. (2013). Synthesis and

characterization of multi-functional linear-dendritic block copolymer for intracellular
delivery of antitumor drugs. International Journal of Pharmaceutics. 452(1-2), 563-573.
10.1016/j.ijpharm.2013.05.003
15.

Elissen-Román, C. C., Fischer, H. H., & Meijer, E. B. (1999). Microphase

separation of diblock copolymers consisting of polystyrene and acid-functionalized
poly(propylene

imine)

dendrimers.

Macromolecules.

32(17),

5525-5531.

10.1021/ma990212k
16.

Zhou, Z., Ma, X., Jin, E., Tang, J., Sui, M., Shen, Y., . . . Radosz, M. (2013). Linear-

dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery.
Biomaterials. 34(22), 5722-5735. 10.1016/j.biomaterials.2013.04.012
17.

Dong, C. M., * and Gang Liu, G. (2013). Linear–dendritic biodegradable block

copolymers: from synthesis to application in bionanotechnology. Polymer Chemistry. 1(4)
46-52. DOI: 10.1039/C2PY20441J
18.

Tomalia, D. A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., . . . Smith,

P. (2002). A new class of polymers: Starburst-dendritic macromolecules. Polymer Journal.
34(5), 132-147.
19.

Esfand, R., & Tomalia, D. A. (2001). Poly(amidoamine) (PAMAM) dendrimers:

From

biomimicry

to

drug

delivery

and

Ltd.10.1016/S1359-6446(01)01757-3

59

biomedical

applications.

Elsevier

20.

Beezer, A. E., King, A. S. H., Martin, I. K., Mitchel, J. C., Twyman, L. J., & Wain,

C. F. (2003). Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes
within

water

soluble

PAMAM

derivatives.

Tetrahedron.

59(22),

3873-3880.

10.1016/S0040-4020(03)00437-X
21.

Chen, C., Chueh, J., Tseng, H., Huang, H., Lee, S. Preparation and characterization

of biodegradable PLA polymeric blends. Biomaterials. 24(7). 2003. 1167-1173.
https://doi.org/10.1016/S0142-9612(02)00466-0.
22.

Kettiger, H., Schipanski, A., & Wick, Peter & Huwyler, J. (2013). . International

Journal of Nanomedicine. 8. 3255-3269. 10.2147/IJN.S49770.

60

